Acetyl l-carnitine (ALC) treatment in elderly patients with fatigue

Archives of Gerontology and Geriatrics

Volumn 46, Issue 2, 2008, Pages 181-190

  Malaguarnera, Michele ^a   Gargante, Maria Pia ^a   Cristaldi, Erika ^a   Colonna, Valentina ^a   Messano, Masa ^b   Koverech, Aleardo ^b   Neri, Sergio ^a   Vacante, Marco ^a   Cammalleri, Lisa ^a   Motta, Massimo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b Sigma Tau SpA   (Italy)

Author keywords

ALC; Chronic fatigue syndrome in the elderly; Cognitive status; l Carnitine; Mental fatigue; Physical fatigue; Physical status; Severity of fatigue

Indexed keywords

LEVACECARNINE;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DYSTHYMIA; EXERCISE; FATIGUE; FATIGUE SEVERITY SCALE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; MOOD DISORDER; MYALGIA; NEUROMUSCULAR DISEASE; PRIORITY JOURNAL; RATING SCALE;

ACETYLCARNITINE; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FATIGUE SYNDROME, CHRONIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MOTOR ACTIVITY; NOOTROPIC AGENTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 38949140508     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archger.2007.03.012     Document Type: Article

References (39)

1. Behan W.M., More I.A., and Behan P.O. Mitochondrial abnormalities in the postviral fatigue syndrome. Acta Neuropathol. (Berlin) 83 (1991) 61-65
2. Buchwald D., Umali P., Umali J., Kith P., Pearlman T., and Komaroff A.L. Chronic fatigue and the chronic fatigue syndrome: prevalence in a Pacific Northwest health care system. Ann. Intern. Med. 123 (1995) 81-88
3. Calabrese P., and Gambassi A. Aging at criticality in model-C dynamics. Phys. Rev. E: Stat. Nonlinear Soft. Matter Phys. 67 (2003) 036111
4. Calvani M., and Arrigoni-Martelli E. Attenuation by acetyl-l-carnitine of neurological damage and biochemical derangement following brain ischemia and reperfusion. Int. J. Tissue React. 21 (1999) 1-6
5. Campos Y., Huertas R., Lorenzo G., Bautista J., Gutierrez E., Aparicio M., Alesso L., and Arenas J. Plasma carnitine insufficiency and effectiveness of l-carnitine therapy in patients with mitochondrial myopathy. Muscle Nerve 16 (1993) 150-153
6. Cavallini G., Caracciolo S., Vitali G., Modenini F., and Biagiotti G. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology 63 (2004) 641-646
7. Chaudhuri A., and Behan P.O. Fatigue in neurological disorders. Lancet 363 (2004) 978-988
8. Cimprich B. Symptom management: loss of concentration. Semin. Oncol. Nurs. 11 (1995) 279-288
9. Costell M., and Grisolia S. Effect of carnitine feeding on the levels of heart and skeletal muscle carnitine of elderly mice. FEBS Lett. 315 (1993) 43-46
10. De Grandis D., and Minardi C. Acetyl-l-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled study. Drugs R. D. 3 (2002) 223-231
11. Folstein M.F., Folstein S.E., and McHughs P.R. Mini mental state: a practical method for grading the cognitive state of patients for the clinician. J. Psychiat. Res. 12 (1975) 189-198
12. Fukuda K., Straus S.E., Hickie I., Sharpe M.C., Dobbins J.G., Komaroff A., and International Chronic Fatigue Syndrome Study Group. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann. Intern. Med. 121 (1994) 953-959
13. Havlik R.J., Yancik R., Long S., Ries L., and Edwards B. The National Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer 74 (1994) 2101-2106
14. Holmes G.P., Kaplan J.E., Gantz N.M., Komaroff A.L., Schonberger L.B., Straus S.E., Jones J.F., Dubois R.E., Cunningham-Rundles C., and Pahwa S. Chronic fatigue syndrome: a working case definition. Ann. Intern. Med. 108 (1988) 387-389
15. Hurst J.W., Morris D.C., and Alexander R.W. The use of the New York Heart Association's classification of cardiovascular disease as a part of the patient's complete problem list. Clin. Cardiol. 22 (1999) 385-390
16. Iossa S., Mollica M.P., Lionetti L., Crescenzo R., Botta M., Barletta A., and Liverini G. Acetyl-l-carnitine supplementation differently influences nutrient partitioning, serum leptin concentration and skeletal muscle mitochondrial respiration in young and old rats. J. Nutr. 132 (2002) 636-642
17. Jason L.A., Taylor R., Wagner L., Holden J., Ferrari J.R., Plioplys A.V., Plioplys S., Lipkin D., and Papernik M. Estimating rates of chronic fatigue syndrome from a community-based sample: a pilot study. Am. J. Commun. Psychol. 23 (1995) 557-668
18. Jones M.G., Goodwin C.S., Amjad S., and Chalmers R.A. Plasma and urinary carnitine and acylcarnitines in chronic fatigue syndrome. Clin. Chim. Acta 360 (2005) 173-177
19. Krupp L.B., La Rocca N.G., Muir-Nash J., and Steinberg A.D. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythema-tosus. Arch. Neurol. 46 (1989) 1121-1123
20. Lee Y.H., Lee K.J., Han G.S., Yoon S.J., Lee Y.K., Kim C.H., and Kim J.L. The development of physical functioning scale for community-dwelling older persons. Korean J. Prev. Med. 35 (2002) 359-374 (in Korean)
21. Lou J.S., Kearns G., Oken B., Sexton G., and Nutt J. Exacerbated physical fatigue and mental fatigue in Parkinson's disease. Movement Disord. 16 (2001) 190-196
22. Malaguarnera M., Pistone G., and Motta M. Mythology in medicine: the elderly and quality of life. Br. Med. J. 311 (1995) 1136-1136
23. Malaguarnera M., Pistone G., Elvira R., Leotta C., Scarpello L., and Liborio R. Effects of l-carnitine in patients with hepatic encephalopathy. World J. Gastroenterol. 11 (2005) 7197-7202
24. Montgomery S.A., Thal L.J., and Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-l-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int. Clin. Psychopharmacol. 18 (2003) 61-71
25. National Cholesterol Education Program, 1994. Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel ii). Circulation 89, 1333-1445.
26. Neri S., Pistone G., Saraceno B., Pennisi G., Luca S., and Malaguarnera M. l-Carnitine decreases severity and type of fatigue induced by interferon-alpha in the treatment of patients with hepatitis C. Neuropsychobiology 47 (2003) 94-97
27. Patrick L. Nutrients and HIV: part three: n-acetylcysteine, alpha-lipoic acid, l-glutamine, and l-carnitine. Altern. Med. Rev. 5 (2000) 290-305
28. Pistone G., Marino A., Leotta C., Dell'Arte S., Finocchiaro G., and Malaguarnera M. Levocarnitine administration in elderly subjects with rapid muscle fatigue: effect on body composition, lipid profile and fatigue. Drugs Aging 20 (2003) 761-767
29. Plioplys A.V., and Plioplys S. Amantidine and l-carnitine treatment of chronic fatigue syndrome. Neuropsychobiology 35 (1997) 16-23
30. Rai G., Wright G., Scott L., Beston B., Rest J., and Exton-Smith A.N. Double-blind, placebo controlled study of acetyl-l-carnitine in patients with Alzheimer's dementia. Curr. Med. Res. Opin. 11 (1990) 638-647
31. Rebouche C.J. Carnitine function and requirements during the life cycle. FASEB J. 6 (1992) 3379-3386
32. Rhodes V.A., Watson P.M., and Hanson B.M. Patients' descriptions of the influence of tiredness and weakness on self-care abilities. Cancer Nurs. 11 (1988) 186-194
33. Salvioli G., and Neri M. l-Acetylcarnitine treatment of mental decline in the elderly. Drugs Exp. Clin. Res. 20 (1994) 169-176
34. Servaes P., Verhagen C.A., and Bleijenberg G. Relations between fatigue, neuro-psychological functioning, and physical activity after treatment for breast carcinoma: daily self-report and objective behavior. Cancer 95 (2002) 2017-2026
35. Sharpe M., Chalder T., Palmer I., and Wessely S. Chronic fatigue syndrome: a practical guide to assessment and management. Gen. Hosp. Psychiat. 19 (1997) 185-199
36. Steele L., Dobbins J.G., Fukuda K., Reves M., Randall B., Koppelman M., and Reeves W.C. The epidemiology of chronic fatigue in San Francisco. Am. J. Med. 105 (1998) 83S-90S
37. Tomassini V., Pozzilli C., Onesti E., Pasqualetti P., Marinelli F., Pisani A., and Fieschi C. Comparison of the effects of acetyl l-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. J. Neurol. Sci. 218 (2004) 103-108
38. Wessely S., and Powell R. Fatigue syndromes: a comparison of chronic postviral fatigue with neuromuscular and affective disorders. J. Neurol. Neurosurg. Psychiat. 52 (1989) 940-948
39. World Medical Association Declaration of Helsinki, 1997. Recommendations guiding physicians in biomedical research involving human subjects. J. Am. Med. Assoc. 277, 925-926.